AIM: Pathological gambling and comorbid alcohol dependence often occur in combination. Disulfiram is one of the proven drugs for alcohol dependence. In addition to its inhibiting acetaldehyde dehydrogenase, disulfiram inhibits dopamine beta-hydroxylase and may thereby increase dopamine and decrease norepinephrine cerebral concentrations. Because there may be common neurochemical substrates and neuronal circuits for pathological gambling and addiction, we wished to explore the effect of disulfiram in gambling. METHOD: We describe the outcome of a patient with alcohol dependence and pathological gambling treated with disulfiram D. RESULTS: During treatment with disulfiram, the patient reported that his desire to gamble disappeared entirely. Follow-up indicated that he has not gambled for >12 months. CONCLUSIONS: Although uncontrolled case observations should be interpreted with caution, disulfiram deserves further investigation in pathological gambling.
AIM: Pathological gambling and comorbid alcohol dependence often occur in combination. Disulfiram is one of the proven drugs for alcohol dependence. In addition to its inhibiting acetaldehyde dehydrogenase, disulfiram inhibits dopamine beta-hydroxylase and may thereby increase dopamine and decrease norepinephrine cerebral concentrations. Because there may be common neurochemical substrates and neuronal circuits for pathological gambling and addiction, we wished to explore the effect of disulfiram in gambling. METHOD: We describe the outcome of a patient with alcohol dependence and pathological gambling treated with disulfiram D. RESULTS: During treatment with disulfiram, the patient reported that his desire to gamble disappeared entirely. Follow-up indicated that he has not gambled for >12 months. CONCLUSIONS: Although uncontrolled case observations should be interpreted with caution, disulfiram deserves further investigation in pathological gambling.
Authors: Robert D Winefield; Anthonius A M Heemskerk; Swetha Kaul; Todd D Williams; Michael J Caspers; Thomas E Prisinzano; Elinore F McCance-Katz; Craig E Lunte; Morris D Faiman Journal: J Pharm Biomed Anal Date: 2015-01-25 Impact factor: 3.935
Authors: Patricia Di Ciano; Daniel F Manvich; Abhiram Pushparaj; Andrew Gappasov; Ellen J Hess; David Weinshenker; Bernard Le Foll Journal: Psychopharmacology (Berl) Date: 2017-10-30 Impact factor: 4.530
Authors: Penelope A Lind; Gu Zhu; Grant W Montgomery; Pamela A F Madden; Andrew C Heath; Nicholas G Martin; Wendy S Slutske Journal: Addict Biol Date: 2012-07-11 Impact factor: 4.280